tetano
Editor, Senior Moderator
Eur J Cancer
. 2022 Apr 26;170:10-16.
doi: 10.1016/j.ejca.2022.03.019. Online ahead of print.
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry
Alessio Cortellini[SUP] 1 [/SUP], Ramon Salazar[SUP] 2 [/SUP], Alessandra Gennari[SUP] 3 [/SUP], Juan Aguilar-Company[SUP] 4 [/SUP], Mark Bower[SUP] 5 [/SUP], Alexia Bertuzzi[SUP] 6 [/SUP], Joan Brunet[SUP] 7 [/SUP], Matteo Lambertini[SUP] 8 [/SUP], Clara Maluquer[SUP] 9 [/SUP], Paolo Pedrazzoli[SUP] 10 [/SUP], Alvin Jx Lee[SUP] 11 [/SUP], MCarmen Carmona-García[SUP] 7 [/SUP], Thomas Newsom-Davis[SUP] 5 [/SUP], Mieke Van Hemelrijck[SUP] 12 [/SUP], Andrea Plaja[SUP] 13 [/SUP], Alberto Zambelli[SUP] 14 [/SUP], Carlo Tondini[SUP] 14 [/SUP], Daniele Generali[SUP] 15 [/SUP], Rossella Bertulli[SUP] 16 [/SUP], Nikolaos Diamantis[SUP] 17 [/SUP], Uma Mukherjee[SUP] 17 [/SUP], Gianpiero Rizzo[SUP] 18 [/SUP], Tamara Yu[SUP] 11 [/SUP], Federica Zoratto[SUP] 19 [/SUP], Riccardo Bruna[SUP] 20 [/SUP], Anna Sureda[SUP] 21 [/SUP], Clara Martinez-Vila[SUP] 9 [/SUP], Luca Cantini[SUP] 22 [/SUP], Francesca Mazzoni[SUP] 23 [/SUP], Federica Grosso[SUP] 24 [/SUP], Alessandro Parisi[SUP] 25 [/SUP], Maristella Saponara[SUP] 26 [/SUP], Aleix Prat[SUP] 27 [/SUP], David J Pinato[SUP] 28 [/SUP], On Covid study group
Affiliations
Abstract
Introduction: A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.
Methods: In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry.
Results: Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8-11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4-3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis.
Conclusion: This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies.
Keywords: COVID-19; Long-term; Outcome; SARS-CoV-2; Sequelae.
. 2022 Apr 26;170:10-16.
doi: 10.1016/j.ejca.2022.03.019. Online ahead of print.
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry
Alessio Cortellini[SUP] 1 [/SUP], Ramon Salazar[SUP] 2 [/SUP], Alessandra Gennari[SUP] 3 [/SUP], Juan Aguilar-Company[SUP] 4 [/SUP], Mark Bower[SUP] 5 [/SUP], Alexia Bertuzzi[SUP] 6 [/SUP], Joan Brunet[SUP] 7 [/SUP], Matteo Lambertini[SUP] 8 [/SUP], Clara Maluquer[SUP] 9 [/SUP], Paolo Pedrazzoli[SUP] 10 [/SUP], Alvin Jx Lee[SUP] 11 [/SUP], MCarmen Carmona-García[SUP] 7 [/SUP], Thomas Newsom-Davis[SUP] 5 [/SUP], Mieke Van Hemelrijck[SUP] 12 [/SUP], Andrea Plaja[SUP] 13 [/SUP], Alberto Zambelli[SUP] 14 [/SUP], Carlo Tondini[SUP] 14 [/SUP], Daniele Generali[SUP] 15 [/SUP], Rossella Bertulli[SUP] 16 [/SUP], Nikolaos Diamantis[SUP] 17 [/SUP], Uma Mukherjee[SUP] 17 [/SUP], Gianpiero Rizzo[SUP] 18 [/SUP], Tamara Yu[SUP] 11 [/SUP], Federica Zoratto[SUP] 19 [/SUP], Riccardo Bruna[SUP] 20 [/SUP], Anna Sureda[SUP] 21 [/SUP], Clara Martinez-Vila[SUP] 9 [/SUP], Luca Cantini[SUP] 22 [/SUP], Francesca Mazzoni[SUP] 23 [/SUP], Federica Grosso[SUP] 24 [/SUP], Alessandro Parisi[SUP] 25 [/SUP], Maristella Saponara[SUP] 26 [/SUP], Aleix Prat[SUP] 27 [/SUP], David J Pinato[SUP] 28 [/SUP], On Covid study group
Affiliations
- PMID: 35576848
- DOI: 10.1016/j.ejca.2022.03.019
Abstract
Introduction: A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.
Methods: In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry.
Results: Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI:8,8-11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range: 1.4-3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis.
Conclusion: This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies.
Keywords: COVID-19; Long-term; Outcome; SARS-CoV-2; Sequelae.